Drugs / VLA1553
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT06106581 | Dec 2023 → Jul 2024 | chikungunya | Valneva Austria GmbH | Completed | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT07133178 | Feb → Dec 2026 | chikungunya | Valneva Austria GmbH | Withdrawn | No outcome recorded |
| Phase 3 | NCT06028841 | Apr → Aug 2024 | chikungunya | Valneva Austria GmbH | Withdrawn | No outcome recorded |
| Phase 3 | NCT04650399 | Feb 2022 → Mar 2023 | chikungunya | Butantan Institute | Completed | No outcome recorded |
| Phase 3 | NCT04838444 | Apr 2021 → Mar 2023 overdue | chikungunya | Valneva Austria GmbH | Active not recruiting | No outcome recorded |
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03382964 Comparator | Mar → Jul 2018 | chikungunya | Valneva Austria GmbH | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT04786444 Comparator | Feb → Jul 2021 | chikungunya | Valneva Austria GmbH | Completed | No outcome recorded |
| Phase 3 | NCT04546724 Comparator | Sep 2020 → May 2021 | chikungunya | Valneva Austria GmbH | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VLA1553 | “Single intramuscular vaccination on Day 1 with VLA1553, a lyophilized live-attenuated Chikungunya vaccine candidate 1x10E4 TCID50 per dose (0.5 mL)” NCT04650399 ↗ |
| Modality | Vaccine | “I.M. vaccination with a live-attenuated Chikungunya virus (CHIKV) vaccine candidate” NCT03382964 ↗ |
| Route | Intramuscular | “Vaccination will be given intramuscularly on Day 0.” NCT03382964 ↗ |